Friday, July 10, 2026

pharma · Relapsing-Remitting Multiple Sclerosis · Spinal Muscular Atrophy

Biogen

Biogen is a pharma organization headquartered in VISAKHAPATNAM, IN. Primary therapeutic focus areas include Relapsing-Remitting Multiple Sclerosis, Spinal Muscular Atrophy, systemic lupus erythematosus, IgA nephropathy,

225 Binney Street, Cambridge, MA 02142, US HQ
7,534 Employees
NMPA registrant Type
Company details
Clinical program

BIIB111

Phase 3 · small molecule · Choroideremia (CHM) X-Linked Retinitis Pigmentosa (XLRP)

BIIB111 for Choroideremia (CHM) X-Linked Retinitis Pigmentosa (XLRP) is a Phase 3 program (small_molecule) at Biogen with 1 ClinicalTrials.gov record(s).

← All Biogen projects Phase 3 small molecule active

Internal code NSR-CHM-OS2 273CH201

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Biogen
Phase
Phase 3
Modality
small_molecule
Indication
Choroideremia (CHM) X-Linked Retinitis Pigmentosa (XLRP)
Status
active
Trials
1

Clinical trials